摘要
肿瘤免疫反应作为一种保护机制,在血液系统肿瘤形成时即自发产生。然而,在临床明确诊断肿瘤之前,活化的免疫细胞和效应细胞因子的存在已经引发多种免疫抑制途径,这些途径相互协同并导致肿瘤抗原特异性T细胞的功能障碍,最终使血液系统肿瘤处于耐受状态。吲哚胺-2,3-双加氧酶(indoleamine 2,3-dioxygenase,IDO)为上述免疫抑制途径的重要成员之一,IDO通过代谢色氨酸,引起反馈性调节,从而限制炎症反应和引起T细胞获得性耐受,最终抑制肿瘤免疫反应。IDO免疫抑制的作用使得IDO抑制剂成为治疗多种肿瘤的重要免疫治疗方法,特别是在血液系统肿瘤中的作用为近些年的研究热点。本文就IDO及其抑制剂在血液系统肿瘤中的治疗作用和预后意义进行综述。
The defense mechanism of tumor immune response is triggered spontaneously with the onset of oncogenesis in hematological malignancy. However, the presence of activated immune cells and effector cytokines activates multiple immunosuppressive pathways prior to clinical diagnosis of tumors, which synergize with each other and cause dysfunction of tumor antigen-specific T cells,ultimately leading to a state of immune tolerance in hematological malignancies. Indoleamine-2,3-dioxygenase（IDO） is an important member of these immunosuppressive pathways, which induces counter-regulation to limit the inflammatory response and triggers T cell-acquired tolerance, eventually inhibiting the tumor immune response. Considering the role of IDO in immunosuppression, IDO inhibitors constitute an important part of the immunotherapeutic arsenal against various tumors, especially hematological malignancies,and have been studied extensively in recent years. This review discusses the significance of IDO and its inhibitors in the treatment and prognosis of hematological malignancies.
作者
吴东维
吴凌
夏冰
张翼鷟
Dongwei Wu;Lin Wu;Bing Xia;Yizhuo Zhang(Department of Hematology, Tianjin Medical University Cancer Institute ＆ Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin＇s Clinical Research Center for Cancer, TianJin 300060, Chin)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2018年第8期413-417,共5页
Chinese Journal of Clinical Oncology
关键词
IDO
免疫抑制
血液系统肿瘤
治疗
预后
IDO, immunosuppression, hematological malignancy, treatment, prognosis
